Deregulation of miR-183 promotes melanoma development via lncRNA MALAT1 regulation and ITGB1 signal activation

Yong Sun, Hongyu Cheng, Guangjun Wang, Guojun Yu, Dawei Zhang, Yibing Wang, Wei Fan, Weixi Yang

Oncotarget · 2016 · 61 citations · 18 references

DOIFull text

Open access

Concepts

Abstract

// Yong Sun 1, * , Hongyu Cheng 1, * , Guangjun Wang 1 , Guojun Yu 1 , Dawei Zhang 1 , Yibing Wang 1 , Wei Fan 2 , Weixi Yang 1 1 Department of Burn and Plastic Surgery, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China 2 Department of Anesthesiology, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China * These authors have contributed equally to this work Correspondence to: Wei Fan, email: fanwei_2020@163.com Weixi Yang, email: SSZX_hayy@163.com Keywords: miR-183, MALAT1, ITGB1, melanoma, competitive endogenous RNA Received: September 01, 2016     Accepted: November 22, 2016     Published: December 10, 2016 ABSTRACT Dysregulation of miR-183 has been recently elucidated in several carcinomas. However, the expression patterns and mechanisms of miR-183 involved in malignant melanoma remain unidentified. Here, we found down-regulation of miR-183 in melanoma tissues and cells. Decreased level of miR-183 was relevant to poor overall survival, while miR-183 up-regulation resulted in a marked suppression of cell growth in vitro and in vivo . We further found that the expression and function of miR-183 were suppressed by MALAT1. Integrin β1 (ITGB1) was then speculated and confirmed as a direct target of miR-183. We also illustrated that MALAT1 may function as a sponge competitive endogenous RNA (ceRNA) for miR-183, and thus regulate the molecular expression of ITGB1. Collectively, we found a new signaling pathway promoting melanoma development by MALAT1-miR-183-ITGB1 axis, which may be clinically valuable as new targets for malignant melanoma therapy.

References

18